hiv envelope protein gp120

Summary

Summary: External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV.

Top Publications

  1. ncbi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
  2. pmc Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
  3. pmc Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
    Jason S McLellan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 480:336-43. 2011
  4. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
  5. pmc Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
    Johannes F Scheid
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Science 333:1633-7. 2011
  6. pmc Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Science 329:811-7. 2010
  7. ncbi Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
    P D Kwong
    Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York 10032, USA
    Nature 393:648-59. 1998
  8. pmc A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield
    Robert Pejchal
    Department of Molecular Biology, Skaggs Institute for Chemical Biology and International AIDS Vaccine Initiative IAVI Neutralizing Antibody Center, nhe Scripps Research Institute, La Jolla, CA 92037, USA
    Science 334:1097-103. 2011
  9. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
  10. pmc Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing
    Xueling Wu
    Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    Science 333:1593-602. 2011

Research Grants

  1. DC-SIGN Inhibitors for the Treatment of HIV Infection
    ALLEN BERNARD REITZ; Fiscal Year: 2013
  2. Transnasal Delivery of Chemokine Analogs in mouse NeuroAIDS Models
    Stuart A Lipton; Fiscal Year: 2013
  3. FcRn-targeted mucosal HIV vaccine
    Xiaoping Zhu; Fiscal Year: 2013
  4. Rational and Combinatorial Design of Immunogens to Elicit 2G12-like Antibodies
    ISAAC KRAUSS; Fiscal Year: 2013
  5. Regulation of cardiac myocytes by HIV-gp120
    MITCHELL SIMON FINKEL; Fiscal Year: 2010
  6. Covalent Vaccine for HIV
    Yasuhiro Nishiyama; Fiscal Year: 2012
  7. PEPTIDE BASED DELIVERY OF HIV IMMUNOGEN
    Lee Riley; Fiscal Year: 1999
  8. HIV gp120 and Prefrontal Cortical Function
    BARRY DALE WATERHOUSE; Fiscal Year: 2013
  9. GP120-MEDIATED UNCOUPLING OF T CELL RECEPTOR
    Frederick Goldman; Fiscal Year: 1993
  10. EXPRESSION OF SIVmac239 GP120 IN TRANSGENIC MAIZE
    JOSEPH JILKA; Fiscal Year: 2001

Detail Information

Publications250 found, 100 shown here

  1. ncbi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
    ..The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control...
  2. pmc Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
    ..The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses...
  3. pmc Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
    Jason S McLellan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 480:336-43. 2011
    ..In addition to structurally defining V1/V2, the results thus identify a paradigm of antibody recognition for highly glycosylated antigens, which-with PG9-involves a site of vulnerability comprising just two glycans and a strand...
  4. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
    ..Exceptionally broad HIV-1 neutralization can be achieved with individual antibodies targeted to the functionally conserved CD4bs of glycoprotein 120, an important insight for future HIV-1 vaccine design...
  5. pmc Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
    Johannes F Scheid
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Science 333:1633-7. 2011
    ..Comparison of the crystal structure of one of the antibodies to the broadly neutralizing antibody VRC01 revealed conservation of the contacts to the HIV spike...
  6. pmc Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Science 329:811-7. 2010
    ..Partial receptor mimicry and extensive affinity maturation thus facilitate neutralization of HIV-1 by natural human antibodies...
  7. ncbi Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
    P D Kwong
    Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York 10032, USA
    Nature 393:648-59. 1998
    ..Our results provide a framework for understanding the complex biology of HIV entry into cells and should guide efforts to intervene...
  8. pmc A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield
    Robert Pejchal
    Department of Molecular Biology, Skaggs Institute for Chemical Biology and International AIDS Vaccine Initiative IAVI Neutralizing Antibody Center, nhe Scripps Research Institute, La Jolla, CA 92037, USA
    Science 334:1097-103. 2011
    ..Furthermore, our data suggest that the high neutralization potency of PGT 127 and 128 immunoglobulin Gs may be mediated by cross-linking Env trimers on the viral surface...
  9. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
    ..The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire...
  10. pmc Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing
    Xueling Wu
    Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    Science 333:1593-602. 2011
    ....
  11. pmc Molecular architecture of native HIV-1 gp120 trimers
    Jun Liu
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Nature 455:109-13. 2008
    ..Our findings elucidate the structure and conformational changes of trimeric HIV-1 gp120 relevant to antibody neutralization and attachment to target cells...
  12. pmc Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
    A Trkola
    Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016, USA
    J Virol 70:1100-8. 1996
    ..consistent with this, antibodies able to block 2G12 binding to recombinant gp120 were not detected in significant quantities in 16 HIV-positive human serum samples...
  13. pmc Structural definition of a conserved neutralization epitope on HIV-1 gp120
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 445:732-7. 2007
    ..A site of vulnerability, related to a functional requirement for efficient association with CD4, can therefore be targeted by antibody to neutralize HIV-1...
  14. pmc Structure of a V3-containing HIV-1 gp120 core
    Chih Chin Huang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    Science 310:1025-8. 2005
    ..The extended nature and antibody accessibility of V3 explain its immunodominance. Together, the results provide a structural rationale for the role of V3 in HIV entry and neutralization...
  15. pmc Increasing the potency and breadth of an HIV antibody by using structure-based rational design
    Ron Diskin
    Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA
    Science 334:1289-93. 2011
    ..Together with the NIH45-46-gp120 structure, these results indicate that gp120 inner domain and bridging sheet residues should be included in immunogens to elicit CD4bs antibodies...
  16. ncbi HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
    Y Feng
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases NIAID, NIH, Bethesda, MD 20892, USA
    Science 272:872-7. 1996
    ..Fusin messenger RNA levels correlated with HIV-1 permissiveness in diverse human cell types. Fusin acted preferentially for T cell line-tropic isolates, in comparison to its activity with macrophagetropic HIV-1 isolates...
  17. pmc Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
    ..Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options...
  18. ncbi Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
    Johannes F Scheid
    Laboratory of Molecular Immunology, The Rockefeller University, New York, New York 10065, USA
    Nature 458:636-40. 2009
    ..Thus, the IgG memory B-cell compartment in the selected group of patients with broad serum neutralizing activity to HIV is comprised of multiple clonal responses with neutralizing activity directed against several epitopes on gp120...
  19. pmc Induction of immunity to human immunodeficiency virus type-1 by vaccination
    M Juliana McElrath
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D3 100, Seattle, WA 98109, USA
    Immunity 33:542-54. 2010
    ....
  20. pmc HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120
    James M Kovacs
    Division of Molecular Medicine, Children s Hospital, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 109:12111-6. 2012
    ..These results, which demonstrate that there are relevant immunologic differences between monomers and high-quality envelope trimers, have important implications for HIV-1 vaccine development...
  21. ncbi Distribution and three-dimensional structure of AIDS virus envelope spikes
    Ping Zhu
    Department of Biological Science and Institute of Molecular Biophysics, Florida State University, Tallahassee, Florida 32306, USA
    Nature 441:847-52. 2006
    ..Reconciling available atomic structures with the three-dimensional whole spike density map yields insights into the orientation of Env spike structural elements and possible structural bases of their functions...
  22. pmc Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer
    Youdong Mao
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA
    Nat Struct Mol Biol 19:893-9. 2012
    ..The cage-like architecture, which is unique among characterized viral envelope proteins, restricts antibody access, reflecting requirements imposed by HIV-1 persistence in the host...
  23. pmc Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01
    Yuxing Li
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 85:8954-67. 2011
    ..It achieves potent neutralization by precisely targeting the CD4bs without requiring alterations of Env spike configuration and by avoiding steric constraints imposed by the quaternary structure of the functional Env spike...
  24. pmc Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops
    Young Do Kwon
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 109:5663-8. 2012
    ..g., the CD4-bound state) provides advantages in terms of HIV-1 Env structural diversity and resistance to antibodies and inhibitors, while maintaining elements essential for entry...
  25. pmc Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
    Erin E H Tran
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, United States of America
    PLoS Pathog 8:e1002797. 2012
    ..These findings suggest a new structural template for designing immunogens that can elicit antibodies targeting HIV at a vulnerable, pre-entry stage...
  26. pmc Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    James M Binley
    IMM2, Department of Immunology, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
    J Virol 78:13232-52. 2004
    ..As well as the significance for vaccine design, our data have implications for passive-immunization studies in countries where clade C viruses are common, given that only MAbs b12 and 4E10 were effective against viruses from this clade...
  27. ncbi Antibody domain exchange is an immunological solution to carbohydrate cluster recognition
    Daniel A Calarese
    Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 300:2065-71. 2003
    ..The unique interdigitation of Fab domains within an antibody uncovers a previously unappreciated mechanism for high-affinity recognition of carbohydrate or other repeating epitopes on cell or microbial surfaces...
  28. pmc The development of CD4 binding site antibodies during HIV-1 infection
    Rebecca M Lynch
    Vaccine Research Center, National Institutes of Health, Bethesda, MD, USA
    J Virol 86:7588-95. 2012
    ....
  29. pmc The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120
    Rogier W Sanders
    Dept of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Virol 76:7293-305. 2002
    ....
  30. ncbi HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells
    James Arthos
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Immunol 9:301-9. 2008
    ..On CD4+ T cells, engagement of alpha4beta7 by gp120 resulted in rapid activation of LFA-1, the central integrin involved in the establishment of virological synapses, which facilitate efficient cell-to-cell spreading of HIV-1...
  31. pmc HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells
    Alyson Yoder
    Department of Molecular and Microbiology, George Mason University, Manassas, VA 20110, USA
    Cell 134:782-92. 2008
    ..Conversely, induction of active cofilin greatly facilitates it. These findings shed light on viral exploitation of cellular machinery in resting T cells, where chemokine receptor signaling becomes obligatory...
  32. pmc Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
    P Roben
    Department of Immunology, Scripps Research Institute, La Jolla, California 92037
    J Virol 68:4821-8. 1994
    ..Apparently, subtle differences in the gp120 epitope recognized allow some members of the group of anti-CD4bs antibodies to bind to the functionally relevant envelope glycoprotein complex and to neutralize virus more efficiently...
  33. pmc HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse
    Clare Jolly
    The Sir William Dunn School of Pathology, University of Oxford, UK
    J Exp Med 199:283-93. 2004
    ..We propose that receptor engagement by Env directs the rapid, actin-dependent recruitment of HIV receptors and adhesion molecules to the interface, resulting in a stable adhesive junction across which HIV infects the target cell...
  34. pmc Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences
    Mark A Jensen
    Department of Microbiology, University of Washington, Seattle, Washington 98195 8070, USA
    J Virol 77:13376-88. 2003
    ..We found that X4 viruses were lost in two ways: by the dying off of an established X4 lineage or by mutation back to low-scoring V3 loops...
  35. pmc Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals
    Yuxing Li
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892 3005, USA
    J Virol 83:1045-59. 2009
    ..These data allow a more detailed understanding of the humoral responses to the HIV-1 Env protein and provide insights regarding the most relevant targets for HIV-1 vaccine design...
  36. ncbi Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    Punnee Pitisuttithum
    Department of Clinical Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
    J Infect Dis 194:1661-71. 2006
    ....
  37. ncbi DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
    T B Geijtenbeek
    Department of Tumor Immunology, University Medical Center St Radboud, Nijmegen, The Netherlands
    Cell 100:587-97. 2000
    ..We propose that DC-SIGN efficiently captures HIV-1 in the periphery and facilitates its transport to secondary lymphoid organs rich in T cells, to enhance infection in trans of these target cells...
  38. pmc The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120
    Christopher N Scanlan
    The Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, United Kingdom
    J Virol 76:7306-21. 2002
    ....
  39. pmc Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120
    Ralph Pantophlet
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:642-58. 2003
    ..These reengineered gp120s are prospective immunogens that may prove capable of eliciting broadly neutralizing antibodies...
  40. pmc Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility
    Marie Pancera
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:1166-71. 2010
    ..A "layered" gp120 architecture thus allows movement among alternative glycoprotein conformations required for virus entry and immune evasion, whereas a beta-sandwich clamp maintains gp120-gp41 interaction and regulates gp41 transitions...
  41. ncbi Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin
    Ming Zhang
    Theoretical Biology Group, Los Alamos National Laboratory, Los Alamos, NM 87544, USA
    Glycobiology 14:1229-46. 2004
    ..Human influenza A hemagglutinin H3 HA1 is accumulating sequons over time, but this trend is not evident in any other avian or human influenza A serotypes...
  42. pmc Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
    Mattia Bonsignori
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 85:9998-10009. 2011
    ..Thus, E.A244, B.9021, and AE.CM243 Envs are three potential immunogen candidates for studies aimed at defining strategies to induce V2/V3 conformational epitope-specific antibodies...
  43. pmc A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America
    PLoS Pathog 6:e1001028. 2010
    ..In approximately half of the donors, key N-linked glycans were critical for expression of the epitopes recognized by the bNAb specificities in the sera...
  44. pmc MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1
    Claudia R Ruprecht
    Institute of Medical Virology, University Hospital Zurich, Switzerland
    J Exp Med 208:439-54. 2011
    ....
  45. pmc Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120
    Lei Chen
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 326:1123-7. 2009
    ..This incompatibility, the consequence of slight differences in CD4BS recognition, renders HIV-1 resistant to all but the most accurately targeted antibodies...
  46. pmc HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes
    Nicole A Doria-Rose
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:3393-7. 2012
    ..Predicted neutralization coverage of a combination of two MAbs reached 97% on a 208-isolate panel...
  47. ncbi HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites
    Peter D Kwong
    Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 420:678-82. 2002
    ..Because this solution is available for cell-surface receptors but not for most antibodies, conformational masking enables HIV-1 to maintain receptor binding and simultaneously to resist neutralization...
  48. ncbi Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells
    C K Leonard
    Department of Medicinal Chemistry, Genentech, Inc, South San Francisco, California 94080
    J Biol Chem 265:10373-82. 1990
    ....
  49. ncbi A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120
    Simon Beddows
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, Room W 805, New York, NY 10021, USA
    Virology 360:329-40. 2007
    ..When antibodies able to neutralize HIV-1(JR-FL) were detected, antigen depletion studies showed they were not directed at the V3 region but were targeted at other, undefined gp120 and also non-gp120 epitopes...
  50. ncbi Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design
    E O Saphire
    Department of Molecular Biology, Department of Immunology, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 293:1155-9. 2001
    ..The structure, together with mutagenesis studies, provides a rationale for the extensive cross-reactivity of b12 and a valuable framework for the design of HIV-1 vaccines capable of eliciting b12-like activity...
  51. pmc Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120
    Anthony P West
    Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA
    Proc Natl Acad Sci U S A 109:E2083-90. 2012
    ..Our results bear on vaccine development and structure-based design to improve the potency and breadth of anti-CD4bs antibodies...
  52. pmc The conformation and orientation of a 27-residue CCR5 peptide in a ternary complex with HIV-1 gp120 and a CD4-mimic peptide
    Einat Schnur
    Department of Structural Biology, Weizmann Institute of Science, Rehovot 76100, Israel
    J Mol Biol 410:778-97. 2011
    ....
  53. pmc Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4
    Chih Chin Huang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 317:1930-4. 2007
    ....
  54. pmc Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity
    O Meucci
    Department of Pharmacological and Physiological Sciences, University of Chicago, 947 E 58th Street MC 0926, Chicago, IL 60637, USA
    Proc Natl Acad Sci U S A 95:14500-5. 1998
    ..Several chemokines were able also to block gp120-induced apoptosis of hippocampal neurons, both in the presence and absence of the glial feeder layer. These data suggest that chemokine receptors may directly mediate gp120 neurotoxicity...
  55. pmc Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure
    Tommi A White
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, United States of America
    PLoS Pathog 6:e1001249. 2010
    ....
  56. ncbi Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission
    Kristen Chalmet
    AIDS Reference Laboratory, Ghent University, Belgium
    J Infect Dis 205:174-84. 2012
    ..The prevalence and correlates of CXCR4-use in recently diagnosed patients and the impact of X4/DM transmission remain largely unknown...
  57. pmc PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4
    Emilia Falkowska
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA
    J Virol 86:4394-403. 2012
    ....
  58. pmc Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies
    Peter Rusert
    Institute of Medical Virology, University Hospital Zurich University of Zurich, 8006 Zurich, Switzerland
    J Exp Med 208:1419-33. 2011
    ..Knowledge on how the V1V2 barrier functions in the context of the trimer to mask conserved epitopes on gp120 may aid future vaccine design...
  59. pmc Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
    Rogier W Sanders
    Department of Microbiology and Immunology, Weill Medical College, Cornell University, New York, New York 10021, USA
    J Virol 76:8875-89. 2002
    ..SOSIP gp140 should be a useful reagent for structural and immunogenicity studies...
  60. pmc Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16
    Katie J Doores
    Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Virol 84:10510-21. 2010
    ..This information may be valuable for the design of immunogens to elicit PG9 and PG16-like antibodies, as well as constructs for cocrystallization studies...
  61. pmc Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens
    Katie J Doores
    Department of Immunology and Microbial Science and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 107:13800-5. 2010
    ..This study revises and extends our understanding of the glycan shield of HIV with implications for AIDS vaccine design...
  62. pmc Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1
    Robert Pejchal
    Department of Molecular Biology, Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 107:11483-8. 2010
    ..Thus, PG9 and PG16 use unique structural features to mediate potent neutralization of HIV-1 that may be of utility in antibody engineering and for high-affinity recognition of a variety of therapeutic targets...
  63. pmc Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1
    Penny L Moore
    Torrey Pines Institute for Molecular Studies, San Diego, CA 92121, USA
    J Virol 80:2515-28. 2006
    ..We hypothesize that these nonfunctional forms of Env on particle surfaces serve to divert the antibody response, helping the virus to evade neutralization...
  64. pmc Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways
    Rong Rong
    Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
    PLoS Pathog 5:e1000594. 2009
    ....
  65. pmc Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization
    James M Binley
    Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, CA 92121, USA
    J Virol 84:5637-55. 2010
    ....
  66. pmc Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque
    Laura M Walker
    Department of Immunology and Microbial Science and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 108:20125-9. 2011
    ....
  67. pmc Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design
    Susan Zolla-Pazner
    Veterans Affairs New York Harbor Healthcare System, Manhattan Campus, New York 10010, USA
    Nat Rev Immunol 10:527-35. 2010
    ..Recombinant immunogens that include these features may provide the means to address the antigenic diversity of HIV-1 and induce protective antibodies that can prevent infection with HIV-1...
  68. ncbi Structural basis for coreceptor selectivity by the HIV type 1 V3 loop
    Timothy Cardozo
    Department of Pharmacology and New York University School of Medicine, New York, NY 10016, USA
    AIDS Res Hum Retroviruses 23:415-26. 2007
    ..The results have additional implications for the design of HIV therapeutics, vaccines, and strategies for monitoring disease progression...
  69. pmc Enhanced HIV-1 neutralization by antibody heteroligation
    Hugo Mouquet
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 109:875-80. 2012
    ..Heterotypic bivalent binding enhanced neutralization compared with the parental antibodies. We conclude that antibody recognition and viral neutralization of HIV can be improved by heteroligation...
  70. pmc Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions
    Andres Finzi
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Department of Pathology, Division of AIDS, Harvard Medical School, Boston, MA 02115, USA
    Mol Cell 37:656-67. 2010
    ..Thus, despite lack of contact with CD4, the gp120 inner-domain layers govern CD4 triggering by participating in conformational transitions within gp120 and regulating the interaction with gp41...
  71. pmc Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state
    Hillel Haim
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Division of AIDS, Harvard Medical School, Boston, MA, USA
    PLoS Pathog 5:e1000360. 2009
    ..This novel strategy for inhibition may be generally applicable to high-potential-energy viral entry machines that are normally activated by receptor binding...
  72. pmc Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding
    Q J Sattentau
    Academic Department of Genito Urinary Medicine, University College and Middlesex School of Medicine, London, United Kingdom
    J Exp Med 174:407-15. 1991
    ..We propose that these events occurring after CD4 binding are integral components of the membrane fusion reaction between HIV or HIV-infected cells and CD4+ cells...
  73. ncbi Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission
    Cynthia A Derdeyn
    Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294 USA
    Science 303:2019-22. 2004
    ..This reveals characteristics of the envelope glycoprotein that influence HIV-1 transmission and may have implications for vaccine design...
  74. pmc N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion
    Shibo Jiang
    Lindsley F Kimball Research Institute, New York Blood Center, 310 E 67th St, New York, NY 10021, USA
    Antimicrob Agents Chemother 48:4349-59. 2004
    ..Therefore, NB-2 and NB-64 can be used as lead compounds toward designing and developing more potent small molecule HIV-1 fusion inhibitors targeting gp41...
  75. pmc The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission
    Fatima Nawaz
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 7:e1001301. 2011
    ..Understanding the structural features that characterize early-transmitting gp120s may aid in the design of an effective gp120-based subunit vaccine...
  76. ncbi HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells
    Sonja I Gringhuis
    Center for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Nat Immunol 11:419-26. 2010
    ..Inhibition of either pathway abrogated replication and prevented HIV-1 transmission. Thus, HIV-1 subverts crucial components of the immune system for replication that might be targeted to prevent infection and dissemination...
  77. pmc Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions
    Juan García-Arriaza
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, Consejo Superior de Investigaciones Cientificas CSIC, Madrid, Spain
    PLoS ONE 5:e12395. 2010
    ....
  78. pmc Energetics of the HIV gp120-CD4 binding reaction
    D G Myszka
    Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA
    Proc Natl Acad Sci U S A 97:9026-31. 2000
    ..These results indicate considerable conformational flexibility within gp120, which may relate to viral mechanisms for triggering infection and disguising conserved receptor-binding sites from the immune system...
  79. pmc Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study
    Patricia Recordon-Pinson
    Laboratoire de Virologie, CHU de Bordeaux, Bordeaux Cedex, France
    Antimicrob Agents Chemother 54:3335-40. 2010
    ..The baseline weighted genotypic sensitivity score was associated with VR at month 6. There were strong arguments in favor of using genotypic coreceptor use assays for determining which patients would respond to CCR5 antagonist...
  80. ncbi Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection
    Neil M Flynn
    University of California at Davis Medical Center, USA
    J Infect Dis 191:654-65. 2005
    ..A vaccine is needed to prevent human immunodeficiency virus type 1 (HIV-1) infection...
  81. ncbi Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA
    Luke C Swenson
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, Canada
    J Acquir Immune Defic Syndr 54:506-10. 2010
    ..Tropism testing should rule out CXCR4-using HIV before treatment with CCR5 antagonists. Currently, the recombinant phenotypic Trofile assay (Monogram) is most widely utilized; however, genotypic tests may represent alternative methods...
  82. pmc Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site
    Yu Feng
    IAVI Neutralizing Antibody Center, Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California 92037, USA
    J Biol Chem 287:5673-86. 2012
    ..These results suggest that some engineered Env proteins may more efficiently direct responses toward the conserved CD4bs and be valuable to elicit antibodies of greater neutralizing capacity...
  83. ncbi Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120
    A Pinter
    Laboratory of Retroviral Biology, Public Health Research Institute, New York, NY 10016, USA
    Vaccine 16:1803-11. 1998
    ....
  84. pmc Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Durham, North Carolina, USA
    J Virol 86:4688-92. 2012
    ..These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities...
  85. ncbi Dissociation of gp120 from HIV-1 virions induced by soluble CD4
    J P Moore
    Chester Beatty Laboratories, Institute of Cancer Research, London, United Kingdom
    Science 250:1139-42. 1990
    ..This may represent the initial stage in virus-cell and cell-cell fusion. Shedding of gp120 from virions induced by sCD4 may also contribute to the mechanism by which these soluble receptor molecules neutralize HIV-1...
  86. pmc Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120
    Anna Forsman
    MRC UCL Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, United Kingdom
    J Virol 82:12069-81. 2008
    ..Antienvelope VHH might also prove useful in defining neutralizing and nonneutralizing epitopes on HIV-1 envelope proteins, with implications for HIV-1 vaccine design...
  87. ncbi Conserved structural elements in the V3 crown of HIV-1 gp120
    Xunqing Jiang
    Department of Biochemistry, New York University School of Medicine, New York, New York, USA
    Nat Struct Mol Biol 17:955-61. 2010
    ..As these regions are targeted by cross-clade neutralizing human antibodies, they provide a blueprint for the design of vaccine immunogens that could elicit broadly cross-reactive protective antibodies...
  88. pmc HIV-1 envelope subregion length variation during disease progression
    Marcel E Curlin
    Department of Medicine, University of Washington School of Medicine, Seattle, Washington, United States of America
    PLoS Pathog 6:e1001228. 2010
    ..V1V2 shortening during early and late-stage infection may reflect ineffective host immunity. Transmission from donors with chronic illness may have caused the modest increase in V1V2 length observed during the course of the pandemic...
  89. pmc A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses
    Juan García-Arriaza
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, Consejo Superior de Investigaciones Cientificas CSIC, Madrid, Spain
    PLoS ONE 6:e24244. 2011
    ..Our observations are relevant for the improvement of MVA vectors as HIV-1 vaccines...
  90. pmc HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells
    Meimei Shan
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, United States of America
    PLoS Pathog 3:e169. 2007
    ..Since such mechanisms might suppress immune responses to Env-containing vaccines, demannosylation may be a way to improve the immunogenicity of gp120 or gp140 proteins...
  91. pmc The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter
    Rebecca M Lynch
    Emory Vaccine Center, Emory University, 954 Gatewood Rd, Atlanta, GA 30329, USA
    J Virol 85:905-15. 2011
    ..Despite this assault, a single amino acid change was sufficient to confer complete escape with minimal impact on replication fitness...
  92. pmc Genotypic prediction of HIV-1 subtype D tropism
    Stéphanie Raymond
    INSERM, U1043, Toulouse, F 31300 France
    Retrovirology 8:56. 2011
    ..Recent studies indicate that the genotypic algorithms used routinely to assess HIV-1 tropism may lack accuracy for non-B subtypes. Little is known about the genotypic determinants of HIV-1 subtype D tropism...
  93. ncbi Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
    Peter D Kwong
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 37:412-25. 2012
    ..The human immune system is capable of developing antibodies that broadly neutralize HIV-1--and an increasingly detailed view is accumulating for how effective immunity against HIV-1 can be generated...
  94. pmc A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120
    Emma T Crooks
    Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, CA 92121, USA
    Virology 366:245-62. 2007
    ..Therefore, to make progress toward a more effective VLP-based vaccine, we will need to find ways to refocus the attention of B cells on native trimers...
  95. ncbi Not so different after all: a comparison of methods for detecting amino acid sites under selection
    Sergei L Kosakovsky Pond
    Antiviral Research Center, University of California San Diego, USA
    Mol Biol Evol 22:1208-22. 2005
    ..We demonstrate our methods on sequence data from the human immunodeficiency virus type 1 env and pol genes and simulated alignments...
  96. pmc R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells
    Claudia Cicala
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:3746-51. 2006
    ..Additionally, signaling by R5 gp120 may facilitate the transmission of R5 viruses by inducing a permissive environment for HIV replication...
  97. ncbi The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection
    F Cocchi
    Institute of Human Virology, University of Maryland Biotechnology Institute and School of Medicine, Baltimore, Maryland 21201, USA
    Nat Med 2:1244-7. 1996
    ..The ability of the chemokines to block the early steps of HIV infection could be exploited to develop novel therapeutic approaches for AIDS...
  98. pmc Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection
    Penny L Moore
    AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa
    PLoS Pathog 5:e1000598. 2009
    ..While the mechanism of neutralization escape appears to vary between individuals, the involvement of limited regions suggests there might be common vulnerabilities in the HIV-1 subtype C transmitted envelope...
  99. pmc Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus
    P D Kwong
    Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York 10032, USA
    J Virol 74:1961-72. 2000
    ..This dependence on charge and not structure may make electrostatic interactions between this basic region and the cell difficult to target therapeutically and may also provide a means of viral escape from immune system surveillance...
  100. pmc Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels
    Bhavna Chohan
    Division of Human Biology, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, C3 168 Seattle, WA 98109 1024, USA
    J Virol 79:6528-31. 2005
    ..Thus, our study also suggests that the extent of glycosylation in the infecting virus could impact disease progression...
  101. ncbi HIV-1 infection and AIDS: consequences for the central nervous system
    M Kaul
    Center for Neuroscience and Aging Research, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Cell Death Differ 12:878-92. 2005
    ..This review will discuss recently uncovered pathologic neuroimmune and degenerative mechanisms contributing to neuronal damage induced by HIV-1 and potential approaches for development of future therapeutic intervention...

Research Grants62

  1. DC-SIGN Inhibitors for the Treatment of HIV Infection
    ALLEN BERNARD REITZ; Fiscal Year: 2013
    ....
  2. Transnasal Delivery of Chemokine Analogs in mouse NeuroAIDS Models
    Stuart A Lipton; Fiscal Year: 2013
    ..This model, as developed by our collaborator Dr. Howard Gendelman and colleagues, while more difficult to utilize, closely mimics human HAND progression and cognitive dysfunction. ..
  3. FcRn-targeted mucosal HIV vaccine
    Xiaoping Zhu; Fiscal Year: 2013
    ....
  4. Rational and Combinatorial Design of Immunogens to Elicit 2G12-like Antibodies
    ISAAC KRAUSS; Fiscal Year: 2013
    ..The focus of this project is to apply knowledge gained from the study of one such antibody, 2G12, to design a vaccine which elicits a neutralizing antibody response by mimicking the 2G12 epitope. ..
  5. Regulation of cardiac myocytes by HIV-gp120
    MITCHELL SIMON FINKEL; Fiscal Year: 2010
    ....
  6. Covalent Vaccine for HIV
    Yasuhiro Nishiyama; Fiscal Year: 2012
    ..Proving preclinical proof-of-principle for covalent vaccination as an effective approach in the present project is an important step in translating this approach for HIV vaccination. ..
  7. PEPTIDE BASED DELIVERY OF HIV IMMUNOGEN
    Lee Riley; Fiscal Year: 1999
    ..of proteins into mammalian cells, and it specifically targets the area of investigation related to the HIV envelope protein gp120. Eliciting a strong CD4 T cell stimulation and cytotoxic T lymphocyte (CTL) response against HIV-1 and ..
  8. HIV gp120 and Prefrontal Cortical Function
    BARRY DALE WATERHOUSE; Fiscal Year: 2013
    ..The work outlined in this proposal will focus on CNS exposure to the HIV envelope protein gp120 in adult and aged rats and its impact on 1) performance of two prefrontal cortex-dependent behavioral ..
  9. GP120-MEDIATED UNCOUPLING OF T CELL RECEPTOR
    Frederick Goldman; Fiscal Year: 1993
    ..Additionally, immunoprecepitation of various kinases will be carried out and their activity and specificity will be assessed using both in vivo and in vitro assays...
  10. EXPRESSION OF SIVmac239 GP120 IN TRANSGENIC MAIZE
    JOSEPH JILKA; Fiscal Year: 2001
    ..This application will serve as a model for the exploration of the use of this methodology to develop HIV vaccines, potentially against a number of important HIV epitopes, for the control of HIV infection. ..
  11. DOMAIN STABILITY AND INTERACTIONS IN CD4
    Christie Brouillette; Fiscal Year: 1993
    ..Also, we have begun to use the V1V2 crystal structure to design new mutants to establish the quantitative importance of specific residues in V1, including residues at the V1-V2 interface, to gp120 recognition...
  12. Mechanisms of HIV Resistance to CCR5 Inhibitors and Consequences for Pathogenesis
    JOHN CHRISTIAN TILTON; Fiscal Year: 2010
    ..Drugs that block the interaction between the HIV envelope protein gp120 and the coreceptor CCR5 are in development and will likely be available for the treatment of patients in ..
  13. HIV, Chemokine Receptors, and Vascular Smooth Muscle
    ALISON SCHECTER; Fiscal Year: 2007
    ..Furthermore, given that HIV patients appear to have accelerated atherosclerosis, these studies will provide potential mechanism(s) responsible for HIV-associated vasculopathies. ..
  14. MOLECULAR CLONING AND EXPRESSION OF HUMAN ANTI-GP120
    Roland Newman; Fiscal Year: 1991
    ..In particular, antibodies are present which are reactive against various epitopes of the HIV envelope protein gp120. Many of these are strain specific and react with hypervariable domains, while others, present at lower ..
  15. MODELING OF CHEMOKINE RECEPTORS WITH LIGANDS AND HIV
    MARIA PATERLINI; Fiscal Year: 2000
    ..modeling techniques will be applied to generate models of pertinent chemokines and of the V3 loop of the HIV envelope protein gp120. Binding of chemokines to the modeled receptors will make use of computations of the electrostatic ..
  16. Neuroprotective agents in HIV-1 associated dementia
    Italo Mocchetti; Fiscal Year: 2009
    ..factor (BDNF) is a prototypical trophic factor that reduces neuronal apoptosis evoked by the HIV envelope protein gp120, used to generate an experimental model of HAD...
  17. PROTECTING CNS CELLS FROM HIV AND HIV-INDUCED INJURY
    David Strayer; Fiscal Year: 2004
    ..We propose to address this therapeutic challenge using rSV40 gene delivery to the CNS, both to protect the brain from HIV infection and to mitigate HIV-induced CNS dysfunction. ..
  18. CCR5 & CXCR4 Antagonist & Agonist Binding Site Structure
    EDWARD DRATZ; Fiscal Year: 2009
    ..HIV entry is a complex process that requires binding of the HIV envelope protein gp120 to a cellular co-receptor (CCR5 or CXCR4)...
  19. Role of Chemokine & T-Cell Receptors in HIV Pathogenesis
    Ramesh Ganju; Fiscal Year: 2009
    ..These studies are designed to identify apoptotic signaling molecules and effector pathways involved in T-cell loss, and thus to provide novel therapeutic targets to combat immune deficiency in AIDS. ..
  20. GP120 AND HIV ASSOCIATED MICROANGIOPATHY
    Gerd Walz; Fiscal Year: 1999
    ..infection, binding by released viral proteins, and/or through interactions of endothelial cells with HIV envelope protein gp120 mediates cell recognition and viral entry; released gp120 may bind cell surface receptors, alter ..
  21. Interactions Of Opioid And Chemokine Receptor Systems in Neurons
    JEEGAR PATEL; Fiscal Year: 2006
    ..In addition, SPECIFIC AIM 2 will evaluate the role of mu-opioid agonists on neuronal cell death by the HIV envelope protein gp120, as well as on the downstream signaling pathways activated by gp120...
  22. MODULATION OF CD8 T CELL FUNCTION BY HIV ENVELOPE PROTEI
    Eric Verdin; Fiscal Year: 2003
    ..abstract_text> ..
  23. DESIGN AND EXPRESSION OF FOLDED GP120 VARIANTS
    Raghavan Varadarajan; Fiscal Year: 2001
    ..The mutant gp120 and CD4 proteins will be expressed and formation of a stable, folded covalent complex between gp120 and CD4 will be attempted. Such a stable complex is an attractive vaccine candidate. ..
  24. SYNTHESIS OF CHLOROPEPTINS, GP120 CD4 BINDING INHIBITORS
    AMOS SMITH; Fiscal Year: 2001
    ..abstract_text> ..
  25. MINORITY PREDOCTORAL FELLOWSHIP
    Elliott Dew; Fiscal Year: 2006
    ..Overall, better understanding of CCR5 inhibitors will enable us to further modify and perfect these compounds. ..
  26. Novel Biological Activities of Anti-Viral Antibody
    Donald Forthal; Fiscal Year: 2006
    ..This project may provide crucial insights for guiding the development of vaccines, immunoprophylaxis and immunotherapy. ..
  27. IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120
    Dennis Burton; Fiscal Year: 2007
    ..Immunization with this molecule should, in principle, be akin to immunizing with the footprint of b12. [unreadable] [unreadable] [unreadable]..
  28. CATALYTIC ANTIBODIES FOR TUMOR IMMUNOTHERAPY
    Sudhir Paul; Fiscal Year: 2001
    ..The investigators expect the proposed studies to generate catalytic Fv constructs capable of permanent and efficient inactivation of EGFR, and to establish the validity of using catalytic Abs for tumor immunotherapy. ..
  29. ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
    Dennis Burton; Fiscal Year: 2007
    ..The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. [unreadable] [unreadable] [unreadable]..
  30. beta-Amyloid Antibodies with Specific Proteolytic Activity
    Sudhir Paul; Fiscal Year: 2008
    ..Proteolytic anti-Abeta Abs capable of preventing the deposition of Abeta and cognitive decline would be candidates for passive immunotherapy of humans with AD. ..
  31. ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPBL-SCID
    Dennis Burton; Fiscal Year: 2001
    ..The emerging results should assist in the design of immunotherapeutic strategies using neutralizing antibodies and illuminate areas of potential concern such as neutralization escape. ..
  32. Proteolytic Antibody HIVcides
    Sudhir Paul; Fiscal Year: 2007
    ..Here, we propose the development of catalytic antibodies capable of degrading the HIV envelope protein gp120 as candidate HIVcides...
  33. RECOMBINANT SINGLE DOMAIN & HYBRID PEPTIDASE ANTIBODIES
    Sudhir Paul; Fiscal Year: 2002
    ....
  34. INNATE AND Ag-ADAPTED CHEMICALLY REACTIVE ANTIBODIES
    Sudhir Paul; Fiscal Year: 2003
    ..Successful execution of this project will provide insight to the genesis of chemically reactive Abs and potentially validate the use CRAs for inhibition and induction of antigen-specific catalytic Abs. ..
  35. NEUTRALIZING ANTIBODIES AGAINST ORTHOPOX VIRUSES
    Dennis Burton; Fiscal Year: 2004
    ..To examine the impact of passive immunization in immunoprophylaxis and immunotherapy of a smallpox-like disease in a non-human primate model, we will use an experimental model of monkeypox virus infection ..
  36. VIRAL EVASION AND HIV ENTRY-BLOCKING STRATEGIES
    Dennis Burton; Fiscal Year: 2004
    ..The studies will reveal how HIV-1 can evade entry-blocking strategies, and may provide important information for vaccine design. ..
  37. THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS
    Dennis Burton; Fiscal Year: 2004
    ....
  38. COOPERATIVE HUMORAL & CELLULAR IMMUNITY AGAINST HIV/SIV
    Dennis Burton; Fiscal Year: 2005
    ..This will provide us with the first opportunity to look at the effects of potent human mAbs on established infection in the presence of functional T cells. ..
  39. gp120 covalent analogs as candidate HIV vaccines
    Sudhir Paul; Fiscal Year: 2008
    ..Novel vaccination strategies and HIV-1 neutralizing Abs will emerge from these studies if the physiological barriers to catalytic Ab synthesis can be bypassed. [unreadable] [unreadable]..
  40. CC Chemokine Secretion to Protect Antigen-Specific CD4 T Cells from HIV
    Catarina E Hioe; Fiscal Year: 2010
    ..Data from this study will provide information about the types of CD4 T cell responses need for protection against HIV and thus should be directly applicable to the development of the much needed HIV vaccines. ..
  41. Prion Transport Across the Blood-Brain Barrier
    William Banks; Fiscal Year: 2009
    ..To cause disease, prions must cross the blood-brain barrier to enter the brain. We will determine how prions cross the BBB. Knowing how prions enter the brain should lead to strategies on how to prevent prion diseases. ..
  42. HIV Vaccines that Elicit Immune Responses to Virus Env
    Catarina E Hioe; Fiscal Year: 2010
    ..These studies will provide information about how to design more immunogenic forms of gp120, how to better stimulate gp120-specific CD4 T cell responses, and how to use the mutated gp120 constructs as HIV vaccines. ..
  43. New Model for NeuroAIDS Utilizing Monocyte-Derived HIV-1
    Tuofu Zhu; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  44. Design and Use of HIV V3 Mimetic Immunogens
    Susan Zolla Pazner; Fiscal Year: 2008
    ..Finally, in Aim 3, we will examine how the intra- and inter-molecular interactions of gpl20 and gp41 affect neutralization sensitivity to anti-V3 mAbs. ..
  45. Neurotrophic factors and HIV-mediated neuronal injury
    Italo Mocchetti; Fiscal Year: 2008
    ....
  46. Apoptotic Mediators in HIV Associated Dementia
    Gwenn Garden; Fiscal Year: 2006
    ..How p53 may promote neurodegeneration through the modulation of caspase enzyme activity will also be studied. ..
  47. DESIGN OF NOVEL IMMUNOGENS AND ADJUVANTS FOR HIV VACCINE
    Barton Haynes; Fiscal Year: 2003
    ..abstract_text> ..
  48. Effect of DC-SIGNR Polymorphisms on HIV-1 Infection
    Tuofu Zhu; Fiscal Year: 2003
    ..These studies should assist in the identification of new therapeutic targets and strategies to protect against HIV-1 transmission and control disease progression. ..
  49. PTS1 Regulation of Brain Met Enk Levels in Alcoholism
    William Banks; Fiscal Year: 2004
    ..abstract_text> ..
  50. NCRR FACSAria Cell Sorter
    Barton Haynes; Fiscal Year: 2004
    ..Advisory committees, institutional support, financial support for continued maintenance, and management plans are in place to insure that the instrument will be fully and appropriately utilized. ..
  51. Mechanisms of HIV Transport Across the BBB
    William Banks; Fiscal Year: 2004
    ....
  52. Neuronal transport of gp120
    Italo Mocchetti; Fiscal Year: 2005
    ..abstract_text> ..
  53. Role of CD14+ Monocytes in HIV-1 Infection
    Tuofu Zhu; Fiscal Year: 2005
    ..Findings from this proposal will provide better understanding of productive infection of HIV-1 in CD 14+ monocytes in vivo, and may also provide great insights to developing new therapeutic strategies to enhance therapy efficacy. ..
  54. Olympus FV-1000 Confocal Microscope
    Gwenn Garden; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  55. Antidepressants and Fibroblast Growth Factor
    Italo Mocchetti; Fiscal Year: 2006
    ..Data from this proposal may help elucidate the therapeutic efficacy of antidepressants in affective disorders. [unreadable] [unreadable]..
  56. Opiate Addiction and HIV-1 Induced Release of Cytokines
    William Banks; Fiscal Year: 2006
    ....
  57. Minimal Levels of HIV-1 in Vaccinated & Exposed Persons
    Tuofu Zhu; Fiscal Year: 2007
    ..These studies should assist definition of virologic and immunologic characteristics required to attenuate and/or substantially control HIV-1 infection, a critical goal of AIDS vaccine development. ..
  58. Neuronal Apoptosis Induced by DNA Damage
    Italo Mocchetti; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  59. CASPASE ENZYMES & APOPTOSIS IN HIV INDUCED NEURAL INJURY
    Gwenn Garden; Fiscal Year: 2003
    ..abstract_text> ..
  60. Implications of HIV in Low HCV Clearance in Chinese IDUs
    Xiao Fang Yu; Fiscal Year: 2007
    ..The results of these studies should provide further insight into the mechanism of HCV clearance and the development of immunity which are critical for the development of effective vaccine and new treatment strategies. ..